|
| Romosozumab治疗骨质疏松的研究进展 |
| Advances in the treatment of osteoporosis with Romosozumab |
| |
| DOI：10.3969/j.issn.1006-7108.2020.07.031 |
| 中文关键词: Romosozumab 骨硬化蛋白 骨质疏松 |
| 英文关键词:romosozumab osclerosin steoporosis |
| 基金项目:陕西省重点研发计划（2017SF-287） |
|
| 摘要点击次数: 806 |
| 全文下载次数: 357 |
| 中文摘要: |
| Romosozumab是一种人源性单克隆抗体药物，在生物体内与骨硬化蛋白相结合可以明显增加骨量形成，同时减少骨吸收，具有双重调节作用，是一种全新类型的治疗骨质疏松药物。适应症主要为绝经后女性骨质疏松患者和具有高骨折倾向的老年男性患者，初步临床试验证明具有良好的疗效和安全性，临床应用前景值得期待。本文将对Romosozumab治疗骨质疏松的研究进展进行综述。 |
| 英文摘要: |
| Romosozumab is a human monoclonal antibody drug, which can significantly increase the bone formation and reduce the bone resorption when combined with osclerotic protein in vivo. It has a dual regulatory effect and is a brand new type of drug for the treatment of osteoporosis. The indications are mainly postmenopausal women with osteoporosis and elderly men with a high tendency to fracture. Preliminary clinical trials have proved that it has good efficacy and safety, and the clinical application prospect is worth looking forward to. This article will review the research progress of Romosozumab in the treatment of osteoporosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |